Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. This phase I trial is studying the side effects and best dose of tipifarnib in
treating patients with relapsed or refractory acute myeloid leukemia